Outlook Therapeutics, Inc. Common Stock
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view OTLK Smart Score
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. Show Less
Recent trades of OTLK by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by OTLK's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to OTLK
Recent picks made for OTLK stock on CNBC
ETFs with the largest estimated holdings in OTLK
Flights by private jets registered to OTLK